Class / Patent application number | Description | Number of patent applications / Date published |
514006000 | Heavy metal containing (e.g., hemoglobin, etc.) | 41 |
20080207491 | Method and composition for treatment and/or prevention of antibiotic-resistant microorganism infections - The present invention relates to a new composition, use and method to improve the cure of infections caused by antibiotic resistant microbial pathogens, in particular beta-lactam resistant microorganisms. Lactoferrin (LF) or Lactoferricin (LFC) can be administrated alone or in combination with antibiotic to affect growth, physiology and morphology of targeted microorganism. Lactoferrin increase susceptibility and can reverse resistance of microorganism to antibiotics. | 08-28-2008 |
20080255032 | METHODS AND COMPOSITIONS FOR PREVENTING AND TREATING AGING OR PHOTODAMAGED SKIN - Disclosed are methods for treating aging and photodamaged skin employing topical application of compositions which comprise at least one peptide manganese complex. Also disclosed are methods wherein the composition further comprises retinol, at least one retinol derivative, or a mixture thereof and methods wherein the composition further comprises active agents selected from active drug substances, emollients, sunscreen agents, skin lightening agents, skin protectants, skin conditioning agents, humectants, and mixtures thereof. | 10-16-2008 |
20080255033 | Metallopeptide gamma-Melanocyte Stimulating Hormone Compounds - Metallopeptides with a sequence of a biologically active gamma-melanocyte stimulating hormone sequence of length n residues, wherein a residue including a nitrogen atom and sulfur atom each available for complexation to a metal ion is inserted at any position from between the two and three position to the C-terminus side of the n position, or alternatively is substituted for the residue at any position from the three position to the n position, with a metal ion complexed thereto, with any proline (Pro) residue which is either of the two residues on the immediately adjacent N-terminus side of the inserted or substituent residue comprising a nitrogen atom and sulfur atom available for complexation to a metal ion is substituted with a homolog. | 10-16-2008 |
20080293619 | COMPOSITIONS AND METHODS FOR TREATING MALARIA WITH CUPREDOXIN AND CYTOCHROME - The present invention relates to cupredoxin and cytochrome and their use, separately or together, to inhibit the spread of parasitemia in mammalian red blood cells and other tissues infected by the malaria parasite, and in particular the parasitemia of human red blood cells by | 11-27-2008 |
20090023632 | Hemoglobin-haptoglobin complexes - Construct-complexes of a hemoglobin, a hepatocyte modifying substance bound to the hemoglobin, and a haptoglobin bound to the hemoglobin, are provided, for administration to mammalian patients. The construct-complex may be formed ex vivo, or a hemoglobin-hepatocyte modifying substance combination may be administered to the patient so that haptoglobin in the mammalian body bonds thereto to form the construct-complex in vivo. Disorders of the liver may be diagnosed and treated using construct-complexes described herein. | 01-22-2009 |
20090062181 | Mineral Collagen Chelates And Methods Of Making And Using Same - Collagen peptide chelated mineral products, pharmaceutical formulations thereof and methods for preparing same are provided. Also provided is a method for generating the optimal size of collagen peptide for optimum mineral chelation as well as optimum biological function for supporting bone health and joint health. Also disclosed are methods of increasing bone density/preventing osteoporosis, of reducing joint pain and/or joint deterioration from osteoarthritis, degenerative joint disease, joint defect, and rheumatoid arthritis. | 03-05-2009 |
20090069217 | Nutrient composition - Provided is a nutrient composition for promoting collagen production, which contains vitamin C, an iron preparation, and collagen as active ingredients, promotes collagen production in a living body such as skin or bone, prevents or treats skin aging or bone and joint diseases, and is an iron preparation-containing composition having stability imparted thereto. Also provided are a food or beverage, a feed, and a medicine each containing the nutrient composition incorporated therein. | 03-12-2009 |
20090075865 | Novel medicament for ameliorating dyskinesia - A novel medicament for treating neurodegenerative diseases, especially for ameliorating dyskinesia, comprising as an active ingredient selenoprotein P and/or a peptide fragment or a series of peptide fragments derived from said protein is provided. The novel medicament for treating neurodegenerative diseases, especially for ameliorating dyskinesia, according to the present invention is suitably applicable to diseases with decrease in motor function. | 03-19-2009 |
20090075866 | METHOD TO ENHANCE HEMODYNAMIC STABILITY USING OXYGEN CARRYING COMPOSITIONS - The present invention relates to methods for enhancing the hemodynamic stability of an individual undergoing surgery by administering a composition comprising a hemoglobin-based oxygen carrier. In one embodiment, the present invention relates to the use of polyalkylene oxide modified hemoglobins with reduced cooperativity and a high oxygen affinity to enhance oxygen offloading as a preventative measure to avoid hemodynamic stability-related complications during surgery. | 03-19-2009 |
20090082257 | MalPEG-Hb conjugate- containing compositions for delivering carbon monoxide (CO) to cells - The present invention relates to compositions for delivering carbon monoxide (CO) to cells using heme proteins as carriers. In one embodiment, the present invention relates to the use of MalPEG surface modified hemoglobin to deliver CO to cells. | 03-26-2009 |
20090131303 | METHODS AND COMPOSITIONS FOR TREATING DRY EYE - The present invention is directed to ophthalmic compositions containing protease-inhibiting peptide substrates. In a preferred embodiment, the protease-inhibiting peptide substrate is gelatin. The compositions may also contain a galactomannan. In a particularly preferred embodiment, the compositions contain gelatin, a galactomannan and a borate salt. The present invention also describes methods of use of these compositions to inhibit protease MMP-9, and methods of topical administration of the compositions to the eye, particularly for the treatment of dry eye. | 05-21-2009 |
20090137458 | METHODS AND COMPOSITIONS FOR INCREASING SKIN REMODELING - Skin remodeling is stimulated at the site of blemished skin using an ionic metal-peptide complex to diminish or remove the skin imperfection. The blemish can be a scar, especially surgical or wound scars, acne scars, keloid scars, and the like, or a skin tag, callus, benign skin mole, stretch marks, facial keratosis, thickened sunspots of the skin, or a vitiligo spot. The peptide-ionic metal complex is comprised of an ionic metal selected from copper(II), tin(II), tin(IV), and zinc(II), and salts thereof, and the peptide component can be a hydrolysis of casein, collagen, elastin, meat products, silk protein, or soybean protein, or a chemically synthesized dipeptide, tripeptide, tetrapeptide or the like which complexes with the ionic metal. | 05-28-2009 |
20090176693 | AGENT FOR MAINTAINING THE HARDNESS OF TOOTH STRUCTURE - Provided are an agent for maintaining hardness of tooth substances and a food or drink for maintaining the hardness of tooth substances, both of which include lactoferrin and iron-lactoferrin as an active ingredient. Lactoferrin and iron-lactoferrin suppress decalcification of enamel by use or ingestion thereof, and hence is effective for the prevention of dental caries. | 07-09-2009 |
20090215670 | Site specific pegylated hemoglobin, method of preparing same, and uses thereof - The present invention provides pegylated hemoglobins comprising a maleimide polyethylene glycol (PEG) conjugated to a thiol moiety of a cysteine residue of hemoglobin, methods of preparing the pegylated hemoglobins, compositions and blood substitutes comprising the pegylated hemoglobins, and methods of treating a subject which comprise administering to the subject blood substitutes comprising vasoinactive pegylated hemoglobins. | 08-27-2009 |
20090239786 | Novel Biomaterial Drug Delivery and Surface Modification Compositions - An antimicrobial coating is provided for use on textiles, medical devices, packaging materials, and the like. | 09-24-2009 |
20090253615 | No-modified hemoglobins and uses therefor - Nitrosylhemoglobin can be produced by introducing gaseous NO into an aqueous solution of hemoglobin. It has been demonstrated that nitrosylhemoglobin in aqueous solution can be converted to SNO-hemoglobin upon introduction of oxygen to the solution, as is postulated to occur in the lungs. Nitrosylhemoglobin can be used in methods to produce the physiological effects of NO, for example, to reduce vasoconstriction and to inhibit platelet aggregation. | 10-08-2009 |
20090270309 | USE OF LACTOFERRIN FRAGMENTS AND HYDROLYSATES - The present invention relates to use of at least one lactoferrin fragment or a lactoferrin hydrolysate or a mixture thereof for stimulating skeletal growth, inhibiting bone resorption, stimulating chondrocyte proliferation, stimulating osteoblast proliferation, inhibiting osteoclast development or treating or preventing a skeletal, joint or cartilage disorder. | 10-29-2009 |
20090281021 | Composition and Method for Treating Iron Deficiency Anemia - A composition comprising heme iron and/or heme iron polypeptide in combination with ionic iron(s) and/or chelated iron(s). Administration of effective dosages of the present composition provides a method for treating and/or preventing iron deficiency anemia, and the physiological, biochemical, morphological, and behavioral manifestations symptomatic of same. | 11-12-2009 |
20090298746 | Pegylated hemoglobin and albumin and uses thereof - The present invention provides PEGylated hemoglobins and PEGylated albumins comprising polyethylene glycol (PEG) conjugated to hemoglobin or to albumin, wherein the PEG is a maleimide PEG, an alkylamide PEG, an iodoacetamide PEG, a p-nitro thio-phenyl PEG, a vinyl sulfone PEG, or a mixed disulfide PEG; and PEGylated albumins and PEGylated hemoglobins comprising polyethylene glycol (PEG) attached to a thiolated amino group of albumin or hemoglobin, wherein the amino group is thiolated using dithio sulfo succinimidyl propionate (DTSSP) or dithiosuccinimidyl propionate (DTSP) or dithiobispropionimidate. The invention also provides methods of preparing PEGylated hemoglobins and PEGylated albumins comprising a) reacting hemoglobin or albumin with a thiolating agent and with a PEGylating agent, and b) capping unPEGylated reactive thiols of hemoglobin or albumin with N-ethyl maleimide. | 12-03-2009 |
20090312238 | Protection Against Oxidative Damage in Cells - The present invention relates to the use of MT as a reducing system for the Msr enzymes and other oxioreductase enzymes which form similar intermediates. Specifically, the invention provides for a reduction in the level of oxidative damage in cells through an increase in levels of MT by administration of suitable compounds, resulting in an increase in the activity of the Msr enzymes. | 12-17-2009 |
20090312239 | PREPARATION, FOR USE, IN PARTICULAR, FOR TISSUE AUGMENTATION AND HEALING - The invention relates to a sterile preparation which can be implanted on or in organic tissues, comprising: a natural or modified globin material which is insoluble at physiological pH and/or a material obtainable from globin which has been modified to be soluble at physiological pH, the said materials being biocompatible and biodegradable in the organism; an agent selected from natural or synthetic polymeric adhesive agents, polymeric tissue enhancement or filling agents, more particularly an agent based on crosslinked hyaluronic acid or on polylactic acid, and a polymeric wound cicatrisation agent, specifically oxidized cellulose; with the provisos that, if the preparation comprises the said material obtainable from globin modified so as to be at least partly soluble, the said polymeric adhesive agent, if present, is not hyaluronic acid or carboxymethylcellulose and the said polymeric enhancement or filling agent, if present, is an agent based on crosslinked hyaluronic acid, and that, if the preparation comprises oxidized cellulose, the latter is present in a proportion greater than that of the said globin material, which in that case is a natural or modified globin material which is insoluble at physiological pH; and the use of this preparation, more particularly for filling or cicatrisation. | 12-17-2009 |
20090318333 | Modified Metallothioneins and Methods for Screening and Treatment of Diseases Associated With Oxidative Stress - The present invention is based on the therapeutic potential of a reduced form of thionein. Accordingly, the invention features modified metallothionein or thionein proteins, for example, where at least one sulfur atom is substituted with selenium (e.g., a cysteine substituted with selenocysteine), and fragments thereof. The invention also features methods for screening for candidate compounds that (i) decrease binding of metal (e.g., zinc) to metallothionein or thionein and (ii) do not change the oxidation state of metallothionein, thionein, or another protein. Also featured are methods for generating modified thionein proteins with reduced metal affinity and methods for treating patients with a disease associated with oxidative stress. | 12-24-2009 |
20090318334 | LACTOFERRIN AS AN AGENT IN THE PREVENTION OF ORGAN TRANSPLANT REJECTION AND GRAFT-VERSUS-HOST-DISEASE - The present invention relates to methods of using lactoferrin (LF) to treat, prevent or reduce the incidence of organ transplant rejection and graft-versus-host-disease. More particularly, the present invention relates to methods of reducing an immune response against miss-matched transplanted organs such as kidney, heart, lung, liver, pancreas and stem cells by administering a composition of lactoferrin to the recipient patients. In addition, this invention relates to the treatment of bone marrow transplant (BMT) donors with lactoferrin to attenuate the development of graft-versus-host-disease in the recipients. Moreover, this invention relates to the treatment of xenograft organ donors with lactoferrin to attenuate the development of graft rejection in the recipients. | 12-24-2009 |
20100009901 | Mineral Amino Acid Polysaccharide Complex - This document provides complexes comprising a mineral-amino acid compound and a polysaccharide. For example, the document provides compositions containing such complexes and methods of making and using such complexes. | 01-14-2010 |
20100022442 | COMPOSITIONS AND METHODS FOR INCREASING SERUM ANTIOXIDANT CONCENTRATIONS, DECREASING SERUM TRIGLYCERIDE LEVELS, INHIBITING INSULIN-RECEPTOR SIGNALING ACTIVITY, INCREASING SERUM GHRELIN LEVELS, AND DECREASING SERUM TNF-ALPHA LEVELS - Compositions and methods are provided for increasing serum antioxidant levels, decreasing serum levels of oxidative chemical species, inhibiting insulin-receptor signaling activity, decreasing triglycerides levels, increasing serum ghrelin levels, and decreasing serum TNF-alpha levels. Compositions provided comprise a mixture of zinc-charged, fragmented proteins derived, for example, from serum or milk. Compositions are administered in a therapeutically effective amount to, for example, reduce oxidative stress levels in a mammalian subject. | 01-28-2010 |
20100029546 | preparation method of galactosyl-has magnetic nanoparticles containing adriamycin - Preparation of galactose albumin adriamycin magnetic nanoparticles: in order to prepare galactose albumin magnetic nanoparticle, cottonseed oil and magnetic nano powder is needed. Mix galactose albumin, adriamycin and magnetic nanoparticle at a proportion, and get the particle through emulsification in cottonseed oil, heating for solidification, and diethyl ether washing. This invention couples galactose to the surface of nanoparticle to form galactose nanoparticle, which targets actively and passively to improve the drug targeting level to liver. Modifying albumin adriamycin magnetic nanoparticles with galactose enhances its targeting level. | 02-04-2010 |
20100035796 | 17-ALPHA-SUBSTITUTED DERIVATIVES OF ESTRADIOL WITH WOUND-HEALING ACTIVITY - The invention relates to 17α-(5-hydroxy-C | 02-11-2010 |
20100035797 | Nitric oxide-blocked cross-linked tetrameric hemoglobin - The present invention includes compositions containing carboxamidomethylated cross-linked hemoglobin where the cysteine moiety of the hemoglobin includes a thiol protecting group and where the hemoglobin has a reduced ability to bind with nitric oxide. Preferably, the hemoglobin is deoxygenated, endotoxin free, and stroma free. The present invention also includes method of preparation, process of preparation and the method of use including supplementing blood volume in mammals and treating disorders in mammals where oxygen delivery agents are of benefit. | 02-11-2010 |
20100035798 | METHODS AND COMPOSITIONS FOR THE TOPICAL OXYGENATION OF HYPOXIC TISSUE - The invention provides methods, delivery devices, and compositions for topically oxygenating hypoxic tissue with a hemoglobin-based oxygen earner (HBOC), such as Oxyglobin (Oxyb) in order to promote wound healing and/or reducing hypoxia in post-harvest transplant tissue. The invention can be used, among other things, to stimulate angiogenesis and blood flow at a wound site, reduce wound dilation, and promote wound contraction, thereby increasing the overall rate of wound healing. The invention can also be used, among other things, to reduce oxidative stress in pre-implantation donor organ tissue, as well as stimulate the proliferation of granulation tissue, vessel growth, and promote epithelial healing in transplant tissue once it has been implanted. | 02-11-2010 |
20100087361 | METHOD TO ENHANCE HEMODYNAMIC STABILITY USING OXYGEN CARRYING COMPOSITIONS - The present invention relates to methods for enhancing the hemodynamic stability of an individual undergoing surgery by administering a composition comprising a hemoglobin-based oxygen carrier. In one embodiment, the present invention relates to the use of polyalkylene oxide modified hemoglobins with reduced cooperativity and a high oxygen affinity to enhance oxygen offloading as a preventative measure to avoid hemodynamic stability-related complications during surgery. | 04-08-2010 |
20100105606 | METHODS FOR MAKING HIGH OXYGEN AFFINITY MODIFIED HEMOGLOBIN FOR OXYGEN TRANSPORT - The present invention relates to blood products, and more particularly to compositions comprising a modified oxygenated hemoglobin having a high affinity for oxygen and methods for making such compositions. Such compositions according to the present invention have better stability to autooxidation and superior oxygen carrying characteristics. | 04-29-2010 |
20100137189 | MODIFIED GLOBIN PROTEINS WITH ALTERED ELECTRON TRANSPORT PATHWAY - The present invention relates to a modified porphyrin-based oxygen-carrying protein, such as haemoglobin, which has been found, in its unmodified state to have a low affinity site of electron transfer and a high affinity electron transfer between a reductant and ferryl haem iron via one or more protein amino acids. The invention provides such proteins that comprise a modification to enhance this pathway. | 06-03-2010 |
20100144595 | Lyophilization of Hemoglobin Solutions - A lyophilized hemoglobin composition and a method for lyophilizing hemoglobin are described. The method of the invention produces a reconstituted hemoglobin solution which is not altered in functional properties from the hemoglobin solution prior to lyophilization. | 06-10-2010 |
20100144596 | An Apo-Ferredoxin Preparation, A Process For Producing Same And Uses Thereof - A process for obtaining a pure preparation of an apo- form of an [Fe | 06-10-2010 |
20100144597 | Novel combinatorial approaches to enhancing oxygen transport to tissues - The subject application provides for a method for enhancing oxygen delivery to a tissue in a subject comprising administering to the subject a composition comprising two or more compounds selected from the group consisting of a hemoglobin based oxygen carrier, a nonhemoglobin based oxygen carrier, a rheologic modulator, a diffusion changing compound, a volume expander, and a vasomodulator. The subject application also provides for a method for enhancing oxygen delivery to a tissue in a subject comprising administering to the subject a composition comprising a perfluorocarbon and one or more compounds selected from the group consisting of a hemoglobin based oxygen carrier, a nonhemoglobin based oxygen carrier, a rheologic modulator, a diffusion changing compound, a volume expander, and a vasomodulator. | 06-10-2010 |
20100160210 | GUANIDINIUM DELIVERY CARRIERS - Disclosed herein are transmembrane transporter compounds containing guanidinium groups. Also disclosed herein are methods for transporting a biologically active moiety across a biological membrane using the transmembrane transporter compounds. Particularly, this invention provides a method for the delivery of a biologically active moiety across the biological membranes of such membranes as endothelial tissues. | 06-24-2010 |
20100173826 | Smooth Muscle Relaxation - The invention relates to methods of inducing smooth muscle relaxation, for example, a method of inducing relaxation of a vascular or a non-vascular muscle or a method of inducing relaxation of the microvasculature, in a subject in need thereof by promoting the accumulation of protoporphyrin IX in the smooth muscle. | 07-08-2010 |
20100173827 | ROLE OF PROLINE RICH PEPTIDES IN CELLULAR COMMUNICATION MECHANISMS AND TREATMENT OF DISEASES - The present invention includes peptide compositions for improving cellular communication mechanisms, repairing metabolic errors, and for treatment of AD, dementia and other neurological conditions. The proline rich peptide complexes (PRPC) of the present invention are isolated from colostrinin and can be added in nutritional and other food supplements. Additionally, the present invention describes novel communication system governing circa two hundreds of different types of cells in each mammal that modulates the activities of the organism through the biological computer present in every living cell. Different type of cells can communicate with other through biological computer connected with five different communication networks. In addition to the biological computer controls cell metabolism and function assigned to a given type of cell. Such system permits smooth cooperation between 10 | 07-08-2010 |
20100197566 | Method and Apparatus for Preparing an Acellular Red Blood Cell Substitute - A process is disclosed for the preparation of an essentially tetramer-free, substantially stroma-free, polymerized, pyridoxylated hemoglobin. Also disclosed is an essentially tetramer-free, substantially stroma-free, polymerized, pyridoxylated hemoglobin product capable of being infused into human patients in an amount of up to about 5 liters. | 08-05-2010 |
20100216695 | SECOND GENERATION LOW OXYGEN AFFINITY PEGYLATED HEMOGLOBINS AS OXYGEN-CARRYING PLASMA EXPANDERS - Provided are hemoglobins having at least two chemical modifications that lower oxygen affinity, hemoglobins chemically modified by the addition of glyceraldehyde-3-phosphate, and hemoglobins having at least two specific chemical modifications. PEGylated versions of these hemoglobins are also provided, as are certain tetraPEGylated and diPEGylated hemoglobins. Methods of modifying a hemoglobin are additionally provided, as are methods of making a hemoglobin. Pharmaceutical compositions and blood substitutes using these hemoglobins are further provided, as are methods of treating a subject using these pharmaceutical compositions and blood substitutes. | 08-26-2010 |
20100234275 | Use Of A High Molecular Weight Extracellular Hemoglobin For The Manufacture Of A Medicament For Treating And/Or Preventing Diseases By Inhibition Of Calcium - The present invent ion relates to the use of a high molecular weight extracellular hemoglobin for the manufacture of a medicament for treating and/or preventing diseases by inhibition of calcium. Advantageously, the extracellular hemoglobin is obtained from Annelids. In particular, the invention concerns the use of a high molecular weight extracellular hemoglobin for the manufacture of a medicament for treating and/or preventing cardiovascular diseases, such as hypertension, angina such as angina pectoris, Raynaud's disease, arteriopathy, tachycardia, vasospasm, ischemia, myocardial infarct ion, congestive heart failure, arrhythmia or cerebrovacular accident. | 09-16-2010 |